Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05180331 · ClinicalTrials.gov registry record · NA

Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial

A NA study of Suicide and Suicidal Ideation, sponsored by Butler Hospital.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05180331 is a NA study of Suicide and Suicidal Ideation that has completed, run by Butler Hospital. The registered enrollment target is 10 participants, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05180331, a NA study of Suicide and Suicidal Ideation, has completed, sponsored by Butler Hospital.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).

Interventions

  • BEHAVIORAL Mobile Application to Prevent Suicide (MAPS)

Study Locations (1)

Rhode Island

  • Butler Hospital - Providence

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-12-14
Est. Completion 2024-05-20
Phase NA

Sponsor

Butler Hospital

103 total trials

What the Registry Record Tells You About NCT05180331

The ClinicalTrials.gov registry entry for NCT05180331 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower). The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Suicide appearing as the primary indexed condition, and to 1 intervention - of which Mobile Application to Prevent Suicide (MAPS) is the first listed.

NCT05180331 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT05180331 about?

NCT05180331 is a clinical study titled "Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial". The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).

What is the current status of trial NCT05180331?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2023-12-14. Estimated completion is 2024-05-20.

What conditions does trial NCT05180331 study?

This clinical trial studies the following conditions: Suicide, Suicidal Ideation, Suicide, Attempted, Suicide and Self-harm.

What interventions are being tested in trial NCT05180331?

The interventions under investigation include: Mobile Application to Prevent Suicide (MAPS) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05180331?

This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05180331 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Suicide

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.